At a glance
- Originator Merck & Co
- Class
- Mechanism of Action 5-lipoxygenase inhibitors; Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 15 Feb 1995 Discontinued-Preclinical for Thrombosis in USA (Unknown route)